Navigation Links
Cynvenio and CollabRx Announce Partnership for Cancer Molecular Diagnostics

Westlake Village, CA (PRWEB) December 11, 2013

Cynvenio, a cancer diagnostics company focused on transforming cancer treatment and management through the genomic analysis of tumor cells in blood, today announced a multi-year agreement with CollabRx, Inc., a data analytics company focused on informing clinical decision making in molecular medicine, to offer clinical actionable reports built from CollabRx data and information services with Cynvenio genomic tests.

Under this agreement, Cynvenio will access multiple CollabRx products including the Genetic Variant Annotation (GVA) ServiceTM to offer clinically relevant data and reporting solutions with Cynvenio’s ClearID Breast Cancer and LiquidBiopsy® genomic testing services. ClearID is a monitoring test for breast cancer survivors at high risk of disease recurrence. The ClearID blood test analyzes circulating tumor cells for cancer-associated genomic mutations which can be used to characterize disease status and available treatment options. Clinicians and researchers ordering genomic tests from Cynvenio will now have the option to also choose GVA-based reporting on identified mutations that includes a summary of the clinical evidence for treatment planning, approved targeted therapies, relevant clinical trials for investigational therapies, and additional references for further research.

"A contextualized interpretation of sequencing results is required to make the results of genomic tests actionable for physicians providing highly personalized cancer treatments to their patients," said André de Fusco, CEO of Cynvenio. "CollabRx has developed a scalable process and software platform to provide key elements of the reporting solution that Cynvenio provides to aid physicians in the clinical interpretation of tumor-specific molecular profiles. We are pleased to be able to include GVA with our molecular testing services."

"Cynvenio has introduced an innovative blood test to help monitor for disease in breast cancer survivors at high risk for recurrence,” said Thomas Mika, Chairman, President & CEO of CollabRx. "Their approach of combining the detection of circulating tumor cells with genomic analysis is important for the early detection of cancer, choice of therapy, and ultimately to achieve the best possible clinical outcomes for breast cancer patients. We chose to extend CollabRx expertise and services to ‘liquid biopsy’ for the first time with Cynvenio because they are at the forefront of the sector with a strong focus on advancing personalized medicine in cancer."

Cynvenio and CollabRx representatives will be on hand to discuss and demonstrate the ClearID Breast Cancer test with the GVA reporting service this week at the San Antonio Breast Cancer Symposium, a leading forum for clinical oncologists specializing in the treatment of breast cancer that is being held from December 10-14 in San Antonio, Texas.

The companion announcement from CollabRx is available on:

About Cynvenio Biosystems, Inc.

Cynvenio is a cancer diagnostics company focused on transforming cancer treatment and management through the molecular analysis of tumor biomarkers in the bloodstream. This expertise has resulted in two distinct product offerings: ClearID Breast Cancer monitoring program and LiquidBiopsy. ClearID Breast Cancer, designed for use by patients and their physicians, is a cancer detection and monitoring program that assesses 50 oncogenes for more than 4,500 genetic mutations using next-generation sequencing. This test and real-time molecular analysis provide actionable information that can inform treatment considerations and help improve treatment outcomes. LiquidBiopsy is designed for industry and academic researchers to identify the presence of tumor-cell genetic mutations in whole blood. Founded in 2008, Cynvenio is headquartered in Westlake Village, Calif. (Los Angeles). For more information visit LiquidBiopsy® is a registered trademark of Cynvenio Biosystems, Inc.

About CollabRx

CollabRx, Inc. is a recognized leader in cloud-based expert systems to inform healthcare decision-making. CollabRx uses information technology to aggregate and contextualize the world’s knowledge on genomics-based medicine with specific insights from the nation’s top cancer experts, starting with the area of greatest need: advanced cancers in patients who have effectively exhausted the standard of care. More information may be obtained at

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Cynvenio Biosystems Receives CLIA Certification for its Genomic Sequencing Laboratory
2. Cynvenio Biosystems to Present Clinical Data on Mutational Analysis of LiquidBiopsy® Tumor Samples at the 2013 ASCO Annual Meeting
3. Washington SmartCEO Announces Portal Solutions as Future 50 Award Winner
4. Barnet Dulaney Perkins Eye Center Regrets to Announce the Passing of David Dulaney, MD
5. InterMune Announces Support of The Pulmonary Fibrosis Foundation Care Center Network and Patient Registry Initiative
6. Cardia 7 Pleased to Announce its Cholesterol Reducing Purified Omega 7
7. Excelera Corp. Announces Commitments by National Leaders
8. Sangamo BioSciences Announces First Presentation Of Data From ZFP Therapeutic Program For Treatment Of Sickle Cell Disease And Beta-Thalassemia At American Society Of Hematology Meeting
9. MiMedx Group Announces Proposed Public Offering of Common Stock
10. Intra-Cellular Therapies Announces Positive Topline Phase II Clinical Results of ITI-007 for the Treatment of Schizophrenia
11. Prova Education Announces Expansion of Its Nationwide Medical Education Series “From Guideline to Practice: Managing Challenging Cases in Primary Care”
Post Your Comments:
(Date:10/13/2015)... ... October 13, 2015 , ... The ... as the Pistoia Alliance continues to drive to increase the organization’s impact on ... is focusing its vision and expanding its work in supporting pre-competitive collaboration in ...
(Date:10/13/2015)... ... October 13, 2015 , ... ... announced that it has received a Phase I Small Business Innovative Research (SBIR) ... Institute of General Medical Sciences (NIGMS), will fund the development of a technique ...
(Date:10/13/2015)... TORONTO , Oct. 13, 2015  Generex Biotechnology Corporation ... entered into a non-binding Letter of Intent (LOI) with MediTemp ... has developed a proprietary cooling technology designed to improve sperm ... the United States and three million men ... 25 and 44 diagnosed as infertile.  For 42% of those ...
(Date:10/13/2015)... Jersey (PRWEB) , ... October 13, 2015 , ... ... enhance the educational opportunities for school age children in the areas of Science, ... for all sectors of the national economy, and the program aims to increase ...
Breaking Biology Technology:
(Date:9/30/2015)... YORK , Sept. 30, 2015  The global glucose ... billion for 2015. So says a new report on the ... diabetes management segment dominate the market, followed by continuous glucose ... publisher. Kalorama reports on the market for these products in its ... ...
(Date:9/28/2015)... Sept. 28, 2015 CLEAR, the ... its expedited traveler service is coming to ... travel, bringing a frictionless experience, serious speed ... "CLEAR offers our travelers an expedited ... said Jim Smith , Executive Director, ...
(Date:9/28/2015)... According to a new market ... (Scanner & Others), Application (Access Control & Others), Industry ... Geography Global - Forecast to 2020", published by MarketsandMarkets, the ... Million by 2020, at a CAGR of 23.40% between ... data T ables and 66 Figures ...
Breaking Biology News(10 mins):